Drug Profile

AV 0113

Alternative Names: AV-0113; Cancer vaccine - Activartis; Cancer vaccine - Trimed; Dendritic cell vaccine - Activartis; Trivax cancer vaccine

Latest Information Update: 12 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Glioma
New Molecular Entity No

No development reported Glioblastoma; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours

08 Sep 2021 No development reported - Phase-II for Glioblastoma (Combination therapy, First-line therapy, Adjuvant therapy) in Austria (Intralymphatic)
04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Prostate-cancer in Austria (Parenteral, Injection)
04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Sarcoma in Austria (Parenteral, Injection)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com